Cytoreduction with Hyperthermic Intraperitoneal Chemotherapy: An appraisal of outcomes and cost at a newly established peritoneal malignancy program

Background Outcome measures following cytoreductive surgery with hyperthermic inraperitoneal chemotherapy (CRS/HIPEC) for peritoneal carcinomatosis in established centers are well defined. However, results from newly emerging U.S. centers have not been reported. Methods This is a retrospective review of a prospectively maintained database of patients with peritoneal malignancies undergoing CRS/HIPEC. Result Fifty-six patients underwent exploratory laparotomy with 36 receiving CRS/HIPEC over 36 months. The median PCI score was 18 and the CC0/1 rate was 92%. Postoperative major morbidity was 16.7% with one perioperative death. The median length of hospital stay and ICU days were nine and three days respectively. Disease free survival in high versus low-grade tumors was 12.6 and 31.0 months (p 0.03) respectively. Average direct cost for patients undergoing CRS/HIPEC was $25,917. Conclusions Our emerging center’s short-term results are comparable to established programs with a trend toward more selective intraoperative judgment on who undergoes CRS/HIPEC.